Tariq Kakish, MD
Internal Medicine · Royal Oak, MINPI 1780752543
Payments from drug & device makers
Across 333 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$641
- AstraZeneca$590
- GSK$577
- Pfizer$409
- AbbVie$367
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,835100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 63 | $1,055 |
| Lilly USA, LLC | 40 | $641 |
| AstraZeneca | 38 | $590 |
| GSK | 36 | $577 |
| Pfizer | 21 | $409 |
| AbbVie(2 entities) | 20 | $367 |
| Amgen | 17 | $306 |
| Vanda Pharmaceuticals Inc. | 8 | $233 |
| Boehringer Ingelheim | 9 | $196 |
| Exact Sciences | 6 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $144 |
| E.r. Squibb & Sons, L.L.C. | 5 | $97 |
| Johnson & Johnson | 6 | $91 |
| Bayer | 4 | $85 |
| Aimmune Therapeutics, Inc. | 4 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $84 |
| Astellas Pharma US Inc | 4 | $69 |
| Idorsia Pharmaceuticals US Inc | 3 | $57 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Merck | 4 | $50 |
| Endo Pharmaceuticals Inc. | 3 | $48 |
| Abbott | 2 | $47 |
| Boston Scientific | 2 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Urovant Sciences Inc | 2 | $37 |
| Dexcom, Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Biogen | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Pulmonx Corporation | 1 | $21 |
| Inari Medical, Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
How this compares
$5,835 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $163,449 |
| MounjaroTirzepatide | 133 | $144,338 |
| FarxigaDapagliflozin Propanediol | 85 | $82,911 |
| JardianceEmpagliflozin | 70 | $81,088 |
| OzempicSemaglutide | 72 | $71,366 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $48,324 |
| JanuviaSitagliptin Phosphate | 40 | $42,341 |
| XifaxanRifaximin | 11 | $36,128 |
| Fondaparinux Sodium | 13 | $26,695 |
| TrulicityDulaglutide | 24 | $23,927 |
| MyrbetriqMirabegron | 38 | $23,046 |
| TradjentaLinagliptin | 26 | $18,866 |
| LinzessLinaclotide | 33 | $18,131 |
| XareltoRivaroxaban | 11 | $15,959 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $14,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $641 | $168,265157 claims |
| PfizerEliquis | $409 | $163,449204 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $196 | $110,399111 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $590 | $93,858112 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $577 | $74,056145 claims |
| Novo NordiskOzempic | $1,055 | $71,36672 claims |
| MerckJanuvia | $50 | $42,34140 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $144 | $36,12811 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $23,04638 claims |
| AbbVieLinzess | $367 | $18,13133 claims |
| Johnson & JohnsonXarelto | $91 | $15,95911 claims |
| NovartisEntresto | $16 | $9,04114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Royal Oak
- Sudipto MukherjeeRoyal Oak$3.1M
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.